ACUITY PHARMACEUTICALS

Serial Number 87791663
606

Registration Progress

Application Filed
Feb 9, 2018
Under Examination
Jun 12, 2018
Approved for Publication
Apr 17, 2018
Published for Opposition
Apr 17, 2018
Registered

Basic Information

Serial Number
87791663
Filing Date
February 9, 2018
Published for Opposition
April 17, 2018
Abandonment Date
January 14, 2019
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 14, 2019
Classes
005 010

Rights Holder

EYEPOINT PHARMACEUTICALS US, INC.

03
Address
480 PLEASANT STREET, SUITE B300
WATERTOWN, MA 02472

Ownership History

pSivida US, Inc.

Original Applicant
03
Watertown, MA

pSivida US, Inc.

Owner at Publication
03
Watertown, MA

EYEPOINT PHARMACEUTICALS US, INC.

New Owner After Publication #1
03
WATERTOWN, MA

Legal Representation

Attorney
Jenevieve Maerker, Esq.

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

23 events
Date Code Type Description
Jan 14, 2019 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Jan 14, 2019 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 12, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 18, 2018 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 18, 2018 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 18, 2018 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 17, 2018 PUBO A PUBLISHED FOR OPPOSITION
Apr 17, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 28, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 8, 2018 ALIE A ASSIGNED TO LIE
Feb 28, 2018 CNRT R NON-FINAL ACTION WRITTEN
Feb 28, 2018 GNRT F NON-FINAL ACTION E-MAILED
Feb 28, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 28, 2018 CNEA R EXAMINERS AMENDMENT -WRITTEN
Feb 28, 2018 GNEA O EXAMINERS AMENDMENT E-MAILED
Feb 28, 2018 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 28, 2018 XAEC I EXAMINER'S AMENDMENT ENTERED
Feb 28, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 27, 2018 DOCK D ASSIGNED TO EXAMINER
Feb 27, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 27, 2018 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 16, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 13, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
House mark used for drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of diseases and conditions, including ocular diseases, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma and diseases and conditions in joints, namely, osteoarthritis, bursitis, fibrotic diseases, and infections
First Use Anywhere: 0
First Use in Commerce: 0
Class 010
House mark for sustained drug delivery systems for pharmaceuticals
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 010

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"